Scientists mix sky's splendid hues to reset circadian clocks
A detailed view of the novel LED device that whose orange and blue wavelengths alternate 19 times per second, resulting in a light that emits a soft white glow. The hand at right is that of ophthalmologist Jay Neitz of the University of Washington School of Medicine. Credit: UW Medicine

Those mesmerizing blue and orange hues in the sky at the start and end of a sunny day might have an essential role in setting humans’ internal clocks.

In new research from the University of Washington in Seattle, a novel LED light that emits alternating wavelengths of orange and blue outpaced two other light devices in advancing melatonin levels in a small group of study participants.

Published in the Journal of Biological Rhythms, the finding appears to establish a new benchmark in humans’ ability to influence their circadian rhythms, and reflects an effective new approach to counteract seasonal affective disorder (SAD).

A raft of health and mood problems have been attributed to out-of-sync circadian rhythms. Such asynchrony is encouraged by seasonal changes, a lack of exposure to natural light, graveyard-shift jobs and flights across multiple time zones.

“Our internal clock tells us how our body’s supposed to act during different times of day, but the clock has to be set, and if our brain is not synced to the time of day, then it’s not going to work right,” said Jay Neitz, a co-author on the paper and a professor of ophthalmology at the UW School of Medicine.

Circadian rhythms are trained and reset every day by the 24-hour solar cycles of light and dark, which stimulate circuits in the eyes that communicate to the brain. With that information, the brain produces melatonin, a hormone that helps organisms become sleepy in sync with the solar night.

People who spend many daily hours in artificial light often have circadian rhythms whose melatonin production lags that of people more exposed to natural light. Many commercial lighting products are designed to offset or counteract these lags.

Most of these products, Neitz said, emphasize blue wavelength because it is known to affect melanopsin, a photopigment in the eyes that communicates with the brain and is most sensitive to blue.






Credit: University of Washington School of Medicine

By contrast, “the light we developed does not involve the melanopsin photopigment,” Neitz explained. “It has alternating blue and orange wavelengths that stimulate a blue-yellow opponent circuit that operates through the cone photoreceptors in the retina. This circuit is much more sensitive than melanopsin, and it is what our brains use to reset our internal clocks.”

The paper’s senior author was James Kuchenbecker, a research assistant professor of ophthalmology at the UW School of Medicine. He sought to compare different artificial lights’ effects on the production of melatonin.

He and colleagues devised and conducted a test of three devices:

  • a white light of 500 lux (a brightness appropriate for general office spaces)
  • a short-wavelength blue LED designed to trigger melanopsin
  • the newly developed LED of blue and orange wavelengths, which alternate 19 times a second to generate a soft white glow

The goal was to see what lighting approach was most effective at advancing the phase of melatonin production among six study participants. All participants underwent the following regimen with exposure to each of the three test lights:

The first evening, multiple saliva samples were taken to discern the baseline onset and peak of the participants’ melatonin production. For each subject, the onset of this phase dictated when they were exposed to the test light for two hours in the morning. That evening, saliva samples were again taken to see whether subjects’ melatonin phase had started earlier relative to their individual baselines.

During each test, exposure to other light sources was controlled. The three test spans were spaced such that subjects could return to their normal baseline phases before starting a new device.

In terms of shifting the melatonin-production phase, the alternating blue-orange LED device worked best, with a phase advance of 1 hour, 20 minutes. The blue light produced a phase advance of 40 minutes. The white, 500-lux light elicited an advance of just 2.8 minutes.

Gesturing toward the light that his team developed, Neitz explained. “Even though our light looks like white to the naked eye, we think your brain recognizes the alternating blue and orange wavelengths as the colors in the sky. The circuit that produced the biggest shift in melatonin wants to see orange and blue.”

More information:
Alexandra Neitz et al, Toward an Indoor Lighting Solution for Social Jet Lag, Journal of Biological Rhythms (2024). DOI: 10.1177/07487304241262918

Citation:
Scientists mix sky’s splendid hues to reset circadian clocks (2024, September 16)
retrieved 21 September 2024
from https://medicalxpress.com/news/2024-09-scientists-sky-splendid-hues-reset.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is 9 times 7?

Explore More

MicroRNA is the Nobel-winning master regulator of the genome – researchers are learning to treat disease by harnessing how it controls genes

When Victor Ambros and Gary Ruvkun discovered a new molecule they called microRNA in the 1980s, it was a fascinating diversion from what for decades had been called the central

Sleep problems in preteens increase risk of suicidal thoughts two years later, study finds

Credit: Pixabay/CC0 Public Domain A new study involving Colorado researchers found that sleep problems among preteens increase their risk of suicidal thoughts two years later, though the researchers urged parents

Drug combination prompts immune response in some resistant pancreatic cancers

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns